NRX Pharmaceuticals Inc (NRXP)
$3.46
$-0.02
(-0.57%)
As on 01-Sep-2026 14:32EDT
Market cap
$154 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-6.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
43,295,767
7 Years Aggregate
CFO
$-102.78 Mln
EBITDA
$-239.34 Mln
Net Profit
$-149.08 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NRX Pharmaceuticals Inc (NRXP)
| 27.7 | 9.8 | -21.7 | 49.1 | 5.4 | -53.4 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
NRX Pharmaceuticals Inc (NRXP)
| 23.2 | 372.2 | -58.6 | -76.8 | -80.4 | 130.2 | 3.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NRX Pharmaceuticals Inc (NRXP)
|
3.5 | 153.7 | 3.4 | -23.5 | -658.1 | -- | -- | 2.9 |
| 82.6 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 360.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 585.9 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.0 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout NRX Pharmaceuticals Inc (NRXP)
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United... States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware. Read more
-
Co-Founder, Chief Scientist Officer & Chairman
Dr. Jonathan C. Javitt M.D., M.P.H.
-
Co-Founder, Chief Scientist Officer & Chairman
Dr. Jonathan C. Javitt M.D., M.P.H.
-
Headquarters
Wilmington, DE
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for NRX Pharmaceuticals Inc (NRXP)
What is the current share price of NRX Pharmaceuticals Inc (NRXP) Today?
The share price of NRX Pharmaceuticals Inc (NRXP) is $3.46 (NASDAQ) as of 01-Sep-2026 14:32 EDT. NRX Pharmaceuticals Inc (NRXP) has given a return of 5.45% in the last 3 years.
What is the current PB & PE ratio of NRX Pharmaceuticals Inc (NRXP)?
Since, TTM earnings of NRX Pharmaceuticals Inc (NRXP) is negative, P/E ratio is not available.
The P/B ratio of NRX Pharmaceuticals Inc (NRXP) is 2.90 times as on 28-Aug-2026, a 44 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.00 |
-5.40 |
2024 |
-0.92 |
-1.00 |
2023 |
-1.28 |
-3.29 |
2022 |
-1.86 |
9.96 |
2021 |
-2.66 |
11.89 |
What is the 52 Week High and Low of NRX Pharmaceuticals Inc (NRXP)?
The 52-week high and low of NRX Pharmaceuticals Inc (NRXP) are Rs 5.06 and Rs 1.62 as of 02-Sep-2026.
What is the market cap of NRX Pharmaceuticals Inc (NRXP)?
NRX Pharmaceuticals Inc (NRXP) has a market capitalisation of $ 154 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in NRX Pharmaceuticals Inc (NRXP)?
Before investing in NRX Pharmaceuticals Inc (NRXP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.